Medical devices need separate regulatory framework
Bio Spectrum|Decemeber 2019
Medical devices need separate regulatory framework
Medical devices need separate regulatory framework

The vast majority of India’s medical devices of which is nearly 80 per cent import-dependent, are unregulated for quality and safety. While many of these products may have regulatory certifications in other countries, the reality is that a considerable number of them are being exported from countries that do not regulate their exports. The medical devices market in India is over $15 billion (Rs 105,000 crore) and projected to grow to $50 billion by 2025 and is the fourth-largest in Asia.

Thirty years have gone by since the 1st medical device was regulated as a drug in 1989. A comprehensive regulatory framework is nearly in sight with the Draft MEDICAL DEVICES (Safety, Effectiveness & Innovation) Bill from NITI Aayog to be shortly proposed as a Separate Law.

Our policymakers in Health Ministry were surprisingly undecided and seemed to be in no urgency to usher in a ‘Patient Safety Medical Devices Law to protect patients, even after the recent ICIJ implant files or J&J incident, or the most recent ban on Transvaginal Pelvic Mesh by US Food and Drug (FDA). As Ministry of Health & Family Welfare (MoHFW) had been surprisingly very reluctant to draft a separate law preferring to attempt to amend the Drugs Act and Central Drugs Standard Control Organization (CDSCO) has a conflict of interest to empower itself the industry watchers are waiting with anxiety the details of the Draft Medical Devices Bill that NITI Aayog is reportedly working upon in consultation with other stakeholder departments and ministries to address the regulatory vacuum & the national patient safety concerns.

Diese Geschichte stammt aus der Decemeber 2019-Ausgabe von Bio Spectrum.

Starten Sie Ihre 7-tägige kostenlose Testversion von Magzter GOLD, um auf Tausende kuratierte Premium-Storys sowie über 8.000 Zeitschriften und Zeitungen zuzugreifen.

Diese Geschichte stammt aus der Decemeber 2019-Ausgabe von Bio Spectrum.

Starten Sie Ihre 7-tägige kostenlose Testversion von Magzter GOLD, um auf Tausende kuratierte Premium-Storys sowie über 8.000 Zeitschriften und Zeitungen zuzugreifen.

WEITERE ARTIKEL AUS BIO SPECTRUMAlle anzeigen
Sartorius Stedim Biotech opens new centre for bioprocess innovation in US
Bio Spectrum

Sartorius Stedim Biotech opens new centre for bioprocess innovation in US

Sartorius Stedim Biotech, a leading partner of the biopharmaceutical industry, has opened its new centre for Bioprocess Innovation in Marlborough, Massachusetts in the US.

time-read
1 min  |
BioSpectrum India Jan 2025
Agilent introduces innovative Mito-rOCR assay kit for mitochondrial research
Bio Spectrum

Agilent introduces innovative Mito-rOCR assay kit for mitochondrial research

Agilent Technologies Inc. has announced the new MitorOCR Assay Kit.

time-read
1 min  |
BioSpectrum India Jan 2025
Qiagen launches AI-extension of Ingenuity Pathway Analysis for automatic interpretation of biological data
Bio Spectrum

Qiagen launches AI-extension of Ingenuity Pathway Analysis for automatic interpretation of biological data

Qiagen has announced the launch of Ingenuity Pathway Analysis (IPA) Interpret, a new feature designed to simplify and accelerate the interpretation of complex biological data.

time-read
1 min  |
BioSpectrum India Jan 2025
Parse Biosciences announces expansion of Evercode BCR product line
Bio Spectrum

Parse Biosciences announces expansion of Evercode BCR product line

Parse Biosciences, a leader in scalable single cell sequencing solutions, has announced the expansion of its Evercode BCR product line to enable applications in mice.

time-read
1 min  |
BioSpectrum India Jan 2025
New technology for unambiguous detection of HIV genome using tailored fluorogenic tests
Bio Spectrum

New technology for unambiguous detection of HIV genome using tailored fluorogenic tests

A team of scientists at Jawaharlal Nehru Centre for Advanced Scientific Research (JNCASR), has developed a novel diagnostic technology known as the GQ Topology-Targeted Reliable Conformational Polymorphism (GQ-RCP) platform.

time-read
1 min  |
BioSpectrum India Jan 2025
Gene mutation likely cause for developing autism in early childhood: RGCB study
Bio Spectrum

Gene mutation likely cause for developing autism in early childhood: RGCB study

Autism, a developmental disorder that causes functional abnormalities in brain development, is caused by a combination of environmental and genetic factors with its symptoms manifesting in childhood as early as the age of two years.

time-read
1 min  |
BioSpectrum India Jan 2025
IIIT-Delhi unveils AI platform for discovering molecules that promote healthy ageing
Bio Spectrum

IIIT-Delhi unveils AI platform for discovering molecules that promote healthy ageing

A team of researchers from Indraprastha Institute of Information Technology Delhi (IIIT-Delhi) has developed AgeXtend, a groundbreaking artificial intelligence (AI)-based platform that is set to transform the search for molecules promoting healthy ageing.

time-read
1 min  |
BioSpectrum India Jan 2025
RSSDI study lays focus on Yoga and Diabetes Prevention
Bio Spectrum

RSSDI study lays focus on Yoga and Diabetes Prevention

Dr Jitendra Singh, Union Minister of State (Independent Charge) for Science and Technology, recently released the landmark study by Research Society for Study of Diabetes in India (RSSDI) on 'Yoga and Diabetes Prevention'.

time-read
1 min  |
BioSpectrum India Jan 2025
Dr Alok Khullar steps in as Group CEO of RJ Corp Healthcare
Bio Spectrum

Dr Alok Khullar steps in as Group CEO of RJ Corp Healthcare

RJ Corp Healthcare, a leading name in the healthcare sector through its renowned entities Cocoon Hospital and Cryoviva Stem Cell Bank, has announced the appointment of Dr Alok Khullar as Group Chief Executive Officer (CEO).

time-read
1 min  |
BioSpectrum India Jan 2025
Entod Pharmaceuticals on-boards Dr Anish Desai as Scientific & Research adviser
Bio Spectrum

Entod Pharmaceuticals on-boards Dr Anish Desai as Scientific & Research adviser

Mumbai-based Entod Pharmaceuticals has appointed Dr Anish Desai as its Scientific and Research Adviser.

time-read
1 min  |
BioSpectrum India Jan 2025